Study of xaluritamig combined with hormone therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of prostate cancer that has spread (metastatic) and have not had treatment for it before.
- Your cancer is high-volume, meaning it has spread to at least 4 bones or to organs like the lungs or liver.
- You have started hormone therapy (either shots or surgery to lower testosterone) within the last 12 weeks, and you may also be taking abiraterone or darolutamide.
- You have not received chemotherapy (docetaxel) or certain other advanced treatments like targeted therapy, immunotherapy, or radioligand therapy.
- Your prostate-specific antigen (PSA) level has not started rising again after an initial drop on hormone therapy.
- You do not have serious uncontrolled infections, autoimmune diseases needing strong immune-suppressing drugs, or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.